Details of the Drug Combination

General Information of Drug Combination (ID: DCRJAVG)

Drug Combination Name
CA4P Ciclopirox
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs CA4P   DM9R0ZL Ciclopirox   DMN5T2A
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SU-DIPG-XIII
Zero Interaction Potency (ZIP) Score: 0.489
Bliss Independence Score: 2.83
Loewe Additivity Score: 1.226
LHighest Single Agent (HSA) Score: 1.471

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CA4P
Disease Entry ICD 11 Status REF
Neuroendocrine cancer 2B72.1 Phase 2 [2]
Ovarian cancer 2C73 Phase 2 [2]
Indication(s) of Ciclopirox
Disease Entry ICD 11 Status REF
Cutaneous candidiasis 1F23.14 Approved [3]
Fungal infection 1F29-1F2F Approved [4]
Mycoses 1F2Z Approved [3]
Onychomycosis EE12.1 Approved [3]
Pityriasis simplex N.A. Approved [3]
Tinea corporis 1F28.Y Approved [3]
Tinea cruris 1F28.3 Approved [3]
Tinea versicolor 1F2D.0 Approved [3]
Tinea pedis 1F28.2 Investigative [3]
Ciclopirox Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HIF-prolyl hydroxylase (HPH) TTJQFBG NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Ciclopirox Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [6]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Activity [7]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [8]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Decreases Degradation [9]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [10]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Increases Stability [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Ciclopirox FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076435.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood. 2009 Oct 1;114(14):3064-73. doi: 10.1182/blood-2009-03-209965. Epub 2009 Jul 9.
7 Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4929-34. doi: 10.1073/pnas.0812308106. Epub 2009 Mar 2.
8 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
9 Non-hypoxic stabilization of hypoxia-inducible factor alpha (HIF-alpha): relevance in neural progenitor/stem cells. Neurotox Res. 2009 May;15(4):367-80. doi: 10.1007/s12640-009-9043-z. Epub 2009 Mar 20.
10 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
11 Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood. 2005 Jun 15;105(12):4613-9. doi: 10.1182/blood-2004-10-3980. Epub 2005 Mar 1.